Compare · ASBP vs NVO
ASBP vs NVO
Side-by-side comparison of Aspire Biopharma Holdings Inc. (ASBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 30497.1x ASBP ($6.4M).
- Over the past year, ASBP is down 98.8% and NVO is down 45.1% - NVO leads by 53.7 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for ASBP).
- NVO has more recent analyst coverage (25 ratings vs 0 for ASBP).
- Company
- Aspire Biopharma Holdings Inc.
- Novo Nordisk A/S
- Price
- $7.37+19.26%
- $43.88-0.20%
- Market cap
- $6.4M
- $195.92B
- 1M return
- +2.57%
- -6.80%
- 1Y return
- -98.82%
- -45.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 5
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ASBP
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Other Events
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
- Aspire Biopharma Issues Shareholder Letter
- Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members
- SEC Form 10-Q filed by Aspire Biopharma Holdings Inc.
- SEC Form SCHEDULE 13G filed by Aspire Biopharma Holdings Inc.
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Aspire Biopharma Holdings Inc.
- SEC Form DEFR14A filed by Aspire Biopharma Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care